drugset / Trial / NCT06906497
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Phase 4
Recruiting
48 enrolled
Johann E Gudjonsson MD PhD
Almirall, S.A. · collabDermira, Inc. · collab
NaSingle-groupOpen-labelBasic science
Summary
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Timeline
- Start
- 2025-07-02
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lebrikizumab | Monoclonal antibody | 250 mg | Subcutaneous |